According to a recent LinkedIn post from Tomoverse Imaging Inc, co‑founder Pascal Thériault‑Lauzier participated on stage at the EuroPCR conference in Paris. The post notes that he led a session focused on optimal projections for bifurcation percutaneous coronary intervention, described as a practical peer‑to‑peer discussion among leading interventional cardiologists.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post highlights its engagement with a key community of clinical decision‑makers in interventional cardiology. For investors, this visibility at a major European cardiovascular meeting may signal strengthening relationships with opinion leaders, which could support future clinical adoption, validate the relevance of Tomoverse’s cardiac imaging focus and enhance its positioning within the medtech and cardiac imaging ecosystem.
The emphasis on collaborative learning and “getting it right for patients” suggests continued alignment with evidence‑based practice trends in cardiology. If Tomoverse can translate this conference exposure into pilot collaborations, data generation or integration into PCI workflows, it could improve its long‑term commercial prospects and competitive stance versus other imaging and guidance technologies in structural and coronary interventions.